Type 2 Diabetes MellitusPhase 3Eluminate-5NCT07662109

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

A Phase 3 study testing Elecoglipron and Dapagliflozin in people with Type 2 Diabetes Mellitus, run by AstraZeneca at 303 sites in 24 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other… Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Type 2 Diabetes Mellitus
What is being tested?: Elecoglipron and Dapagliflozin
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 2,000 participants
Where: 303 sitesin 24 countries
Study dates: 6 Jul 2026to 5 Jul 2028
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Who cannot join

Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (New York Heart Association IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Trial locations and contacts

303 sites in 24 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

303 sites in 24 countries

China48 sites, 47 recruiting

Research Site
Baotou
Not yet recruiting
Research Site
Beijing, 100044
Recruiting
Research Site
Beijing, 100050
Not yet recruiting
Research Site
Beijing, 102218
Not yet recruiting
Research Site
Changde, 415000
Not yet recruiting
Research Site
Changsha, 410015
Recruiting
Research Site
Changzhou, 272100
Not yet recruiting
Research Site
Chengdu, 610078
Not yet recruiting
Research Site
Chengdu, 611130
Recruiting
Research Site
Chenzhou, 423000
Not yet recruiting
Research Site
Chifeng, 024000
Not yet recruiting
Research Site
Hangzhou, 310014
Not yet recruiting
Research Site
Hefei, 230601
Recruiting
Research Site
Huai'an, 223005
Recruiting
Research Site
Jinan, 250031
Recruiting
Research Site
Jincheng, 048000
Recruiting
Research Site
Jining, 272006
Not yet recruiting
Research Site
Jinzhou Shi, 121001
Recruiting
Research Site
Kaifeng, 475000
Recruiting
Research Site
Langfang, 065000
Not yet recruiting
Research Site
Liangyugang, 222002
Not yet recruiting
Research Site
Luoyang, 471009
Not yet recruiting
Research Site
Meihekou, 135022
Not yet recruiting
Research Site
Nanjing, 210011
Not yet recruiting
Research Site
Nantong, 226001
Not yet recruiting
Research Site
Nanyang, 473009
Recruiting
Research Site
Pinggu, 101200
Recruiting
Research Site
Pingxiang, 337055
Not yet recruiting
Research Site
Sanya, 572000
Withdrawn
Research Site
Shanghai, 200062
Not yet recruiting
Research Site
Shanghai, 201199
Not yet recruiting
Research Site
Shantou, 515065
Not yet recruiting
Research Site
Shenyang, 110004
Not yet recruiting
Research Site
Shenyang, 110023
Recruiting
Research Site
Shijiazhuang, 050000
Not yet recruiting
Research Site
Shijiazhuang, 050001
Not yet recruiting
Research Site
Tianjin, 300000
Not yet recruiting
Research Site
Wuhan, 430010
Not yet recruiting
Research Site
Wuhu, 241004
Recruiting
Research Site
Xi'an, 710077
Not yet recruiting
Research Site
Xiangyang, 441000
Not yet recruiting
Research Site
Xianyang, 712000
Not yet recruiting
Research Site
Xuzhou, 221000
Not yet recruiting
Research Site
Xuzhou, 221009
Not yet recruiting
Research Site
Yan’an, 716000
Not yet recruiting
Research Site
Yueyang, 414000
Not yet recruiting
Research Site
Zhumadian, 463000
Recruiting
Research Site
Zibo, 255499
Not yet recruiting

Other trials in China

United States45 sites, 43 recruiting

Research Site
Albuquerque, New Mexico, 87112
Recruiting
Research Site
Annapolis, Maryland, 21401
Not yet recruiting
Research Site
Atlanta, Georgia, 30315
Not yet recruiting
Research Site
Bakersfield, California, 93309
Not yet recruiting
Research Site
Beachwood, Ohio, 44122
Not yet recruiting
Research Site
Boston, Massachusetts, 02114
Not yet recruiting
Research Site
Boston, Massachusetts, 02115
Not yet recruiting
Research Site
Brooklyn, New York, 11201
Recruiting
Research Site
Chicago, Illinois, 60640
Recruiting
Research Site
Dallas, Texas, 75230
Recruiting
Research Site
Elkhorn, Nebraska, 68022
Not yet recruiting
Research Site
Evansville, Indiana, 47714
Not yet recruiting
Research Site
Huntsville, Alabama, 35801
Not yet recruiting
Research Site
Kingsport, Tennessee, 37660
Recruiting
Research Site
Kingwood, West Virginia, 26537
Recruiting
Research Site
Lake City, Florida, 32055
Recruiting
Research Site
Lakeland, Florida, 33813
Recruiting
Research Site
Layton, Utah, 84041
Not yet recruiting
Research Site
Little Rock, Arkansas, 72205
Recruiting
Research Site
Los Angeles, California, 90017
Recruiting
Research Site
Lutherville-Timonium, Maryland, 21093
Not yet recruiting
Research Site
Maumee, Ohio, 43537
Recruiting
Research Site
McKinney, Texas, 75069
Not yet recruiting
Research Site
Mobile, Alabama, 36608
Not yet recruiting
Research Site
Nashville, Tennessee, 37203
Recruiting
Research Site
Newport News, Virginia, 23606
Recruiting
Research Site
Norman, Oklahoma, 73069
Not yet recruiting
Research Site
Ontario, California, 91762
Not yet recruiting
Research Site
Oxon Hill, Maryland, 20745
Recruiting
Research Site
Paris, Texas, 75462
Recruiting
Research Site
Philadelphia, Pennsylvania, 19114
Not yet recruiting
Research Site
Raleigh, North Carolina, 27607
Not yet recruiting
Research Site
Redmond, Washington, 98052
Not yet recruiting
Research Site
Ridgeland, Mississippi, 39157
Recruiting
Research Site
Rosedale, New York, 11422
Not yet recruiting
Research Site
San Antonio, Texas, 78258
Not yet recruiting
Research Site
Sheffield, Alabama, 35660
Not yet recruiting
Research Site
Sioux City, Iowa, 51106
Not yet recruiting
Research Site
Skokie, Illinois, 60077
Not yet recruiting
Research Site
South Jordan, Utah, 84095
Withdrawn
Research Site
Toms River, New Jersey, 08755
Not yet recruiting
Research Site
Troy, Michigan, 48098
Recruiting
Research Site
Vienna, Virginia, 22182
Not yet recruiting
Research Site
Webster, Texas, 77598
Withdrawn
Research Site
Zachary, Louisiana, 70791
Not yet recruiting

Other trials in United States

India17 sites, 17 recruiting

Research Site
Bangalore, 560 092
Not yet recruiting
Research Site
Belagavi, 590006
Not yet recruiting
Research Site
Belagavi, 590010
Not yet recruiting
Research Site
Calicut, 673008
Not yet recruiting
Research Site
Chennai, 600086
Not yet recruiting
Research Site
Coimbatore, 641018
Not yet recruiting
Research Site
Guwahati, 781032
Not yet recruiting
Research Site
Indore, 452008
Not yet recruiting
Research Site
Jaipur, 302017
Not yet recruiting
Research Site
Kochi, 682040
Not yet recruiting
Research Site
Kochi, 682041
Not yet recruiting
Research Site
Lucknow, 226030
Not yet recruiting
Research Site
Madurai, 625020
Not yet recruiting
Research Site
Mumbai, 400012
Not yet recruiting
Research Site
Nagpur, 440010
Not yet recruiting
Research Site
New Delhi, 11029
Not yet recruiting
Research Site
Thiruvananthapuram, 695031
Not yet recruiting

Other trials in India

Germany16 sites, 14 recruiting

Research Site
Berlin, 13597
Recruiting
Research Site
Cologne, 51069
Not yet recruiting
Research Site
Damme, 49401
Not yet recruiting
Research Site
Deggingen, 73326
Not yet recruiting
Research Site
Duisburg, 47269
Not yet recruiting
Research Site
Essen, 45355
Recruiting
Research Site
Falkensee, 14612
Suspended
Research Site
Frankfurt, 60596
Recruiting
Research Site
Hamburg, 22607
Recruiting
Research Site
Leipzig, 04249
Recruiting
Research Site
Münster, 48145
Recruiting
Research Site
Nittendorf, 93152
Recruiting
Research Site
Pohlheim, 35415
Recruiting
Research Site
Villingen-Schwenningen, 78048
Withdrawn
Research Site
Wallerfing, 94574
Not yet recruiting
Research Site
Weinheim, 69469
Recruiting

Other trials in Germany

Japan16 sites, 15 recruiting

Research Site
Chūōku, 103-0027
Recruiting
Research Site
Fukuoka, 813-0044
Not yet recruiting
Research Site
Hachioji-shi, 192-0083
Recruiting
Research Site
Ichikawa-shi, 272-8516
Recruiting
Research Site
Kamakura-shi, 247-0055
Not yet recruiting
Research Site
Kamakura-shi, 247-0056
Not yet recruiting
Research Site
Kishiwada-shi, 596-8501
Recruiting
Research Site
Kitakyushu, 805-8508
Not yet recruiting
Research Site
Meguro-ku, 153-0053
Recruiting
Research Site
Mito, 310-0826
Not yet recruiting
Research Site
Sapporo, 060-0061
Recruiting
Research Site
Shinjuku-ku, 160-0008
Recruiting
Research Site
Soka-shi, 340-0015
Not yet recruiting
Research Site
Tama-shi, 206-0033
Withdrawn
Research Site
Yamato-shi, 242-0004
Recruiting
Research Site
Yokohama, 232-0064
Not yet recruiting

Other trials in Japan

South Korea12 sites, 12 recruiting

Research Site
Busan, 49241
Not yet recruiting
Research Site
Goyang-si, 411-706
Recruiting
Research Site
Guri-si, 11923
Recruiting
Research Site
Gwangju, 61453
Recruiting
Research Site
Gyeonggi-do, 13620
Recruiting
Research Site
Seoul, 01830
Not yet recruiting
Research Site
Seoul, 03722
Recruiting
Research Site
Seoul, 06273
Recruiting
Research Site
Seoul, 07345
Not yet recruiting
Research Site
Seoul, 136-705
Not yet recruiting
Research Site
Suwon, 16499
Not yet recruiting
Research Site
Yangsan, 50612
Recruiting

Other trials in South Korea

Taiwan12 sites, 12 recruiting

Research Site
Changhua, 500
Recruiting
Research Site
Kaohsiung City, 80756
Recruiting
Research Site
Kaohsiung City, 813
Recruiting
Research Site
New Taipei City, 220
Recruiting
Research Site
New Taipei City, 24352
Not yet recruiting
Research Site
Taichung, 40201
Recruiting
Research Site
Taichung, 40705
Recruiting
Research Site
Taichung, 433004
Recruiting
Research Site
Tainan, 70403
Recruiting
Research Site
Tainan County, 71044
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taoyuan, 333
Not yet recruiting

Other trials in Taiwan

Brazil11 sites, 11 recruiting

Research Site
Barretos, 14784-400
Not yet recruiting
Research Site
Brasília, 71625-009
Not yet recruiting
Research Site
Campinas, 13060-803
Not yet recruiting
Research Site
Curitiba, 80030-480
Not yet recruiting
Research Site
Fortaleza, 60426-000
Not yet recruiting
Research Site
Natal, 59020-500
Recruiting
Research Site
Porto Alegre, 90630-165
Not yet recruiting
Research Site
Rio de Janeiro, 22270-060
Not yet recruiting
Research Site
São José dos Campos, 12243-280
Not yet recruiting
Research Site
São Paulo, 01228-200
Not yet recruiting
Research Site
São Paulo, 04012-180
Not yet recruiting

Other trials in Brazil

South Africa11 sites, 11 recruiting

Research Site
Brackenfell, 7560
Recruiting
Research Site
Cape Town, 7500
Not yet recruiting
Research Site
Cape Town, 7570
Recruiting
Research Site
Claremont, 7708
Recruiting
Research Site
Durban, 4091
Recruiting
Research Site
Durban, 4093
Not yet recruiting
Research Site
eMkhomazi, 4170
Recruiting
Research Site
Johannesburg, 1827
Not yet recruiting
Research Site
KwaDukuza, 4449
Not yet recruiting
Research Site
Paarl, 7646
Not yet recruiting
Research Site
Pretoria, 0083
Not yet recruiting

Other trials in South Africa

Ukraine11 sites, 10 recruiting

Research Site
Kyiv, 02002
Not yet recruiting
Research Site
Kyiv, 03037
Not yet recruiting
Research Site
Kyiv, 03049
Not yet recruiting
Research Site
Kyiv, 03057
Not yet recruiting
Research Site
Kyiv, 04114
Not yet recruiting
Research Site
Kyiv, 04210
Not yet recruiting
Research Site
Lviv, 79010
Recruiting
Research Site
Lviv, 79016
Recruiting
Research Site
Uzhhorod, 88002
Recruiting
Research Site
Uzhhorod, 88014
Withdrawn
Research Site
Vinnytsia, 21001
Recruiting

Other trials in Ukraine

United Kingdom10 sites, 10 recruiting

Research Site
Blackburn, BB2 1AX
Not yet recruiting
Research Site
Dundee, DD1 9SY
Recruiting
Research Site
Guisborough, TS14 7DJ
Recruiting
Research Site
Nantwich, CW5 5NX
Not yet recruiting
Research Site
Rotherham, S65 1DA
Not yet recruiting
Research Site
Thetford, IP24 1JD
Recruiting
Research Site
Weston-super-Mare, BS24 7PR
Recruiting
Research Site
Witney, OX28 6JS
Recruiting
Research Site
Woodbridge, IP136TH
Not yet recruiting
Research Site
Yate, BS37 4AX
Recruiting

Other trials in United Kingdom

Argentina9 sites, 9 recruiting

Research Site
Buenos Aires, C1012AAR
Not yet recruiting
Research Site
Buenos Aires, C1120AAC
Recruiting
Research Site
Buenos Aires, C1425AGC
Not yet recruiting
Research Site
Caba, C1128AAF
Not yet recruiting
Research Site
Ciudad de Buenos Aires, C1094AAD
Not yet recruiting
Research Site
Mar del Plata, B7600GNY
Not yet recruiting
Research Site
Rosario, S2000CVD
Not yet recruiting
Research Site
San Nicolás, B2900DMH
Not yet recruiting
Research Site
San Vicente, 5006
Not yet recruiting

Other trials in Argentina

Poland9 sites, 9 recruiting

Research Site
Bialystok, 15-897
Recruiting
Research Site
Częstochowa, 42-217
Recruiting
Research Site
Kielce, 25-355
Recruiting
Research Site
Lodz, 90-338
Recruiting
Research Site
Lublin, 20-718
Not yet recruiting
Research Site
Poznan, 60-354
Recruiting
Research Site
Radom, 26-600
Recruiting
Research Site
Warsaw, 00-124
Recruiting
Research Site
Warsaw, 02-507
Recruiting

Other trials in Poland

Czechia8 sites, 8 recruiting

Research Site
Hradec Králové, 500 02
Recruiting
Research Site
Humpolec, 396 01
Recruiting
Research Site
Jílové u Prahy, 254 01
Not yet recruiting
Research Site
Ostrava, 702 00
Not yet recruiting
Research Site
Prague, 147 00
Not yet recruiting
Research Site
Prague, 149 00
Recruiting
Research Site
Prague, 160 00
Not yet recruiting
Research Site
Příbram, 261 01
Not yet recruiting

Other trials in Czechia

Greece8 sites, 8 recruiting

Research Site
Alexandroupoli, 68100
Not yet recruiting
Research Site
Athens, 115 25
Recruiting
Research Site
Athens, 11527
Not yet recruiting
Research Site
Athens, 17562
Recruiting
Research Site
Ioannina, 45110
Recruiting
Research Site
Thessaloniki, 54635
Recruiting
Research Site
Thessaloniki, 54642
Recruiting
Research Site
Thessaloniki, 54645
Recruiting

Other trials in Greece

Mexico8 sites, 8 recruiting

Research Site
Cuernavaca, 62250
Not yet recruiting
Research Site
Cuernavaca, 62448
Not yet recruiting
Research Site
Guadalajara, 44600
Not yet recruiting
Research Site
Guadalajara, 44650
Not yet recruiting
Research Site
Guadalajara, 44670
Not yet recruiting
Research Site
Monterrey, 64460
Not yet recruiting
Research Site
San Luis Potosí City, 78200
Not yet recruiting
Research Site
Zapopan, 45116
Not yet recruiting

Other trials in Mexico

Slovakia8 sites, 8 recruiting

Research Site
Bojnice, 97201
Not yet recruiting
Research Site
Bratislava, 81108
Recruiting
Research Site
Lučenec, 984 01
Not yet recruiting
Research Site
Námestovo, 029 01
Recruiting
Research Site
Rožňava, 048 01
Not yet recruiting
Research Site
Trebišov, 075 01
Not yet recruiting
Research Site
Vrútky, 038 61
Recruiting
Research Site
Žilina, 010 01
Not yet recruiting

Other trials in Slovakia

Thailand8 sites, 8 recruiting

Research Site
Bangkok, 10400
Not yet recruiting
Research Site
Banphaeo, 74120
Recruiting
Research Site
Changwat Sara Buri, 18000
Not yet recruiting
Research Site
Khlong Luang, 12120
Recruiting
Research Site
Khon Kaen, 40002
Not yet recruiting
Research Site
Muang, 70000
Not yet recruiting
Research Site
Mueang, 20000
Recruiting
Research Site
Ratchathewi, 10400
Not yet recruiting

Other trials in Thailand

Denmark7 sites, 7 recruiting

Research Site
Aarhus N, 8200
Not yet recruiting
Research Site
Esbjerg, 6700
Recruiting
Research Site
Gandrup, 9362
Recruiting
Research Site
Herlev, 2730
Recruiting
Research Site
Hillerød, 3400
Recruiting
Research Site
Hvidovre, 2650
Not yet recruiting
Research Site
Odense, 5000
Recruiting

Other trials in Denmark

Hungary7 sites, 6 recruiting

Research Site
Budapest, 1036
Not yet recruiting
Research Site
Budapest, 1089
Suspended
Research Site
Debrecen, 4032
Not yet recruiting
Research Site
Salgótarján, 3100
Not yet recruiting
Research Site
Szeged, 6725
Not yet recruiting
Research Site
Szolnok, 5000
Not yet recruiting
Research Site
Zalaegerszeg, 8900
Not yet recruiting

Other trials in Hungary

Malaysia7 sites, 6 recruiting

Research Site
Alor Star, 05400
Recruiting
Research Site
Ipoh, 30450
Withdrawn
Research Site
Kangar, 01000
Recruiting
Research Site
Kuala Lumpur, 59100
Recruiting
Research Site
Sarawak Miri, 98000
Recruiting
Research Site
Seremban, 70300
Recruiting
Research Site
Seri Manjung, 32040
Recruiting

Other trials in Malaysia

Turkey (Türkiye)7 sites, 7 recruiting

Research Site
Ankara, 06540
Not yet recruiting
Research Site
Ankara, 6200
Not yet recruiting
Research Site
Gaziantep, 27470
Not yet recruiting
Research Site
Istanbul, 34010
Not yet recruiting
Research Site
Istanbul, 34265
Not yet recruiting
Research Site
Istanbul, 34384
Not yet recruiting
Research Site
Konya, 42130
Not yet recruiting

Other trials in Turkey (Türkiye)

Vietnam7 sites, 7 recruiting

Research Site
Hanoi, 10000
Not yet recruiting
Research Site
Hồ Chí Minh, 700000
Not yet recruiting
Research Site
Ho Chi Minh City, 700000
Not yet recruiting
Research Site
Hochiminh, 700000
Not yet recruiting
Research Site
Hochiminh City, 700000
Not yet recruiting
Research Site
Huế, 530000
Not yet recruiting
Research Site
Rach Gia, 920000
Not yet recruiting

Other trials in Vietnam

Puerto Rico1 site, 1 recruiting

Research Site
San Juan, 00918
Not yet recruiting

Other trials in Puerto Rico

About this study

Official title: A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

Conditions: Type 2 Diabetes Mellitus
Being tested: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Medical subject headings: Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ElecoglipronDrug
Elecoglipron is administered orally once daily.
DapagliflozinDrug
Dapagliflozin administered orally once daily.
Elecoglipron-matched placeboDrug
A placebo matching elecoglipron administered orally once daily.
Dapagliflozin-matched placeboDrug
A placebo matching dapagliflozin administered orally once daily.

Study groups in NCT07662109
Study group	Role	What they receive
Elecoglipron dose level 1 + dapagliflozin	Experimental	Participants will receive elecoglipron at dose level 1 and dapagliflozin, administered orally once daily. Receives: Drug: Elecoglipron; Drug: Dapagliflozin
Elecoglipron dose level 2 + dapagliflozin	Experimental	Participants will receive elecoglipron at dose level 2 and dapagliflozin, administered orally once daily. Receives: Drug: Elecoglipron; Drug: Dapagliflozin
Elecoglipron dose level 1 + dapagliflozin-matched placebo	Experimental	Participants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily. Receives: Drug: Elecoglipron; Drug: Dapagliflozin-matched placebo
Elecoglipron dose level 2 + dapagliflozin-matched placebo	Experimental	Participants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily. Receives: Drug: Elecoglipron; Drug: Dapagliflozin-matched placebo
Elecoglipron-matched placebo + dapagliflozin	Active comparator	Participants will receive elecoglipron-matched placebo + dapagliflozin, administered orally once daily. Receives: Drug: Dapagliflozin; Drug: Elecoglipron-matched placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Change from baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline to Week 40

Secondary outcomes (10)

Change from baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline to Week 40
Achievement of HbA1c < 7% (53 mmol/mol)
Measured: Week 40
Percent change in body weight
Measured: Baseline to Week 40
Change from baseline in body weight
Measured: Baseline to Week 40
Change from baseline in Fasting Plasma Glucose (FPG)
Measured: Baseline to Week 40
Change from baseline in daily mean 7-point Self-Monitored Blood Glucose (SMBG)
Measured: Baseline to Week 40
Achievement of ≥ 5% weight loss from baseline
Measured: Baseline to Week 40
Change from baseline in Systolic Blood Pressure (SBP)
Measured: Baseline to Week 40
Change from baseline in Diastolic Blood Pressure (DBP)
Measured: Baseline to Week 40
Time to initiation of rescue medication over 40 weeks
Measured: Baseline to Week 40

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

6 Jul 20265 Jul 2028

First posted23 Jun 2026
Study start6 Jul 2026
Primary completion5 Jul 2028 (estimated)
Study completion5 Jul 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 2,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07662109
Sponsor's protocol ID: D7261C00003
Other IDs: 2025-523941-81-00, 2025
Acronym: Eluminate-5
Status last verified: Oct 2026
First submitted: 18 Jun 2026
Last updated: 30 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes Mellitus trials

Study at a glance

From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
ClinicalTrials.gov ID: NCT07662109
Acronym / sponsor ID: Eluminate-5 / D7261C00003
Conditions: Type 2 Diabetes Mellitus
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 2,000 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 6 Jul 2026 (actual)
Primary completion: 5 Jul 2028 (estimated)
Study completion: 5 Jul 2028 (estimated)
First posted: 23 Jun 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 5

Arm	Type	Receives
Elecoglipron dose level 1 + dapagliflozin	Experimental	Drug: Elecoglipron, Drug: DapagliflozinParticipants will receive elecoglipron at dose level 1 and dapagliflozin, administered orally once daily.
Elecoglipron dose level 2 + dapagliflozin	Experimental	Drug: Elecoglipron, Drug: DapagliflozinParticipants will receive elecoglipron at dose level 2 and dapagliflozin, administered orally once daily.
Elecoglipron dose level 1 + dapagliflozin-matched placebo	Experimental	Drug: Elecoglipron, Drug: Dapagliflozin-matched placeboParticipants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily.
Elecoglipron dose level 2 + dapagliflozin-matched placebo	Experimental	Drug: Elecoglipron, Drug: Dapagliflozin-matched placeboParticipants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily.
Elecoglipron-matched placebo + dapagliflozin	Active comparator	Drug: Dapagliflozin, Drug: Elecoglipron-matched placeboParticipants will receive elecoglipron-matched placebo + dapagliflozin, administered orally once daily.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Key exclusion criteria (7 listed)

Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ElecoglipronElecoglipron is administered orally once daily.	Drug	Elecoglipron dose level 1 + dapagliflozin, Elecoglipron dose level 1 + dapagliflozin-matched placebo, Elecoglipron dose level 2 + dapagliflozin, Elecoglipron dose level 2 + dapagliflozin-matched placebo
DapagliflozinDapagliflozin administered orally once daily.	Drug	Elecoglipron dose level 1 + dapagliflozin, Elecoglipron dose level 2 + dapagliflozin, Elecoglipron-matched placebo + dapagliflozin
Elecoglipron-matched placeboA placebo matching elecoglipron administered orally once daily.	Drug	Elecoglipron-matched placebo + dapagliflozin
Dapagliflozin-matched placeboA placebo matching dapagliflozin administered orally once daily.	Drug	Elecoglipron dose level 1 + dapagliflozin-matched placebo, Elecoglipron dose level 2 + dapagliflozin-matched placebo

Primary outcome

Change from baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline to Week 40

10 secondary outcomes

Change from baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline to Week 40
Achievement of HbA1c < 7% (53 mmol/mol)
Time frame: Week 40
Percent change in body weight
Time frame: Baseline to Week 40
Change from baseline in body weight
Time frame: Baseline to Week 40
Change from baseline in Fasting Plasma Glucose (FPG)
Time frame: Baseline to Week 40
Change from baseline in daily mean 7-point Self-Monitored Blood Glucose (SMBG)
Time frame: Baseline to Week 40
Achievement of ≥ 5% weight loss from baseline
Time frame: Baseline to Week 40
Change from baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline to Week 40
Change from baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline to Week 40
Time to initiation of rescue medication over 40 weeks
Time frame: Baseline to Week 40

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for Type 2 Diabetes Mellitus

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

303 sites in 24 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Elecoglipron and Dapagliflozin in people with Type 2 Diabetes Mellitus, run by AstraZeneca at 303 sites in 24 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 303 sites in China, United States, India, Germany, Japan and 19 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline to Week 40). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07662109.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.